Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Drug Resistance

  Free Subscription

Articles published in Antivir Ther

Retrieve available abstracts of 12 articles:
HTML format
Text format

Single Articles

    February 2017
  1. BISSIO E, Barbas MG, Kademian S, Bouzas MB, et al
    Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3147.
    PubMed     Text format     Abstract available

  2. KREUTZWISER D, Sheehan N, Dayneka N, Lemire B, et al
    Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3139.
    PubMed     Text format     Abstract available

    January 2017
  3. PORTER DP, Kulkarni R, Garner W, Miller MD, et al
    Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/ tenofovir DF or efavirenz/emtricitabine/ tenofovir DF through 96 weeks.
    Antivir Ther. 2017 Jan 16. doi: 10.3851/IMP3128.
    PubMed     Text format     Abstract available

  4. MARGOT N, Cox S, Das M, McCallister S, et al
    Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide or elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Antivir Ther. 2017 Jan 11. doi: 10.3851/IMP3125.
    PubMed     Text format     Abstract available

  5. SIMONETTI FR, Cattaneo D, Zanchetta N, Giacomet V, et al
    Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for TDM.
    Antivir Ther. 2017 Jan 4. doi: 10.3851/IMP3122.
    PubMed     Text format     Abstract available

  6. DONG H, Zhou B, Kang H, Jin W, et al
    Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients.
    Antivir Ther. 2017;22:43-51.
    PubMed     Text format     Abstract available

    November 2016
  7. GILL VC, Lynch T, Ramazani S, Krentz HB, et al
    Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Antivir Ther. 2016 Nov 2. doi: 10.3851/IMP3105.
    PubMed     Text format     Abstract available

    September 2016
  8. CAPETTI AF, Orofino G, Sterrantino G, Cossu MV, et al
    Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3095.
    PubMed     Text format     Abstract available

    May 2016
  9. ARCHAMPONG TN, Boyce CL, Lartey M, Sagoe KW, et al
    HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Antivir Ther. 2016 May 11. doi: 10.3851/IMP3055.
    PubMed     Text format     Abstract available

    March 2016
  10. MIKULA JM, Manion MM, Maldarelli F, Suarez LM, et al
    Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy.
    Antivir Ther. 2016 Mar 8. doi: 10.3851/IMP3040.
    PubMed     Text format     Abstract available

    November 2015
  11. TAMBUYZER L, Thys K, Hoogstoel A, Nijs S, et al
    Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Antivir Ther. 2015 Nov 13. doi: 10.3851/IMP3011.
    PubMed     Text format     Abstract available

  12. NDAHIMANA JD, Riedel DJ, Muhayimpundu R, Nsanzimana S, et al
    HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.
    Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3005.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.